Erez Aminov - 28 May 2025 Form 4 Insider Report for Telomir Pharmaceuticals, Inc. (TELO)

Reporting relationship: CEO and Chairman, Director
Issuer ticker: TELO
Reported as of: 28 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 May 2025, 20:00:11 UTC
Prior SEC filing: 04 Feb 2025
Next SEC filing: 03 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Erez Aminov

Filing notes and source

Key filing fact

Erez Aminov filed Form 4 for Telomir Pharmaceuticals, Inc. (TELO) on 30 May 2025.

Key facts

This page summarizes Erez Aminov's Form 4 filing for Telomir Pharmaceuticals, Inc. (TELO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 May 2025, 20:00.

Change

Previous filing in this sequence was filed on 04 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001986112 Primary reporting owner

Aminov Erez

Relationship: CEO and Chairman, Director
Address: C/O TELOMIR PHARMACEUTICALS, INC., 100 SE 2ND ST, SUITE 200 #1009, MIAMI,
Signature: /s/ Erez Aminov
Signature date: 30 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TELO transaction Derivative

Non-Qualified Options

Award

Transaction value: $0
Shares: +2,000,000
Change %
Price: $0.000000
Shares after: 2,000,000
Date: 28 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,000,000
Exercise price: $2.10
Footnotes: F1, F2

TELO transaction Derivative

Restricted Stock Units (RSUs)

Award

Transaction value: $0
Shares: +400,000
Change %
Price: $0.000000
Shares after: 400,000
Date: 28 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on May 27, 2025.

Footnote F2

The stock options were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). The stock options are fully vested as of the date of grant.

Footnote F3

Each restricted stock unit represents a right to receive one share of Issuer's common stock.

Footnote F4

The RSUs were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Plan. The RSUs are fully vested as of the date of grant.

Footnote F5

Each restricted stock unit represents a right to receive one share of Issuer's common stock.